Breast cancer, Internal medicine, Oncology, Cancer and Neoadjuvant therapy are his primary areas of study. His Breast cancer research incorporates elements of Immunology, Cancer research, Clinical trial and Chemotherapy. His work on Internal medicine is being expanded to include thematically relevant topics such as Gynecology.
His Oncology research is multidisciplinary, incorporating perspectives in Randomized controlled trial, Surgery, Pathology, Gene expression profiling and Triple-negative breast cancer. The concepts of his Cancer study are interwoven with issues in Mutation and AKT1, Protein kinase B. His work deals with themes such as Survival rate, Prospective cohort study and Chemotherapy regimen, which intersect with Neoadjuvant therapy.
W. Fraser Symmans mostly deals with Breast cancer, Internal medicine, Oncology, Cancer and Chemotherapy. His Breast cancer research is multidisciplinary, relying on both Cancer research, Surgery and Pathology. His studies deal with areas such as Clinical trial, Trastuzumab, Cyclophosphamide, Triple-negative breast cancer and Cohort as well as Oncology.
W. Fraser Symmans has researched Cancer in several fields, including Phenotype and Endocrinology. The various areas that W. Fraser Symmans examines in his Chemotherapy study include Anthracycline and Predictive marker. His Neoadjuvant therapy research integrates issues from Regimen and Clinical endpoint.
His scientific interests lie mostly in Breast cancer, Internal medicine, Oncology, Cancer and Neoadjuvant therapy. His Breast cancer study incorporates themes from Outcome data, Regimen, Transcriptome, Targeted therapy and Stage. His Internal medicine and Chemotherapy, MammaPrint, Clinical trial, Clinical endpoint and Proportional hazards model investigations all form part of his Internal medicine research activities.
His Oncology study combines topics in areas such as Guideline, Triple-negative breast cancer, Trastuzumab and Cohort. His Cancer research includes themes of High risk patients, Gynecology and Therapeutic regimen. As a part of the same scientific family, he mostly works in the field of Neoadjuvant therapy, focusing on Randomized controlled trial and, on occasion, Progression-free survival and Confirmatory trial.
His primary areas of investigation include Breast cancer, Internal medicine, Oncology, Neoadjuvant therapy and Guideline. W. Fraser Symmans works mostly in the field of Breast cancer, limiting it down to concerns involving Gene and, occasionally, Concordance correlation coefficient. His work on Predictive biomarker, Stromal tumor and Metastatic breast cancer as part of general Internal medicine research is frequently linked to Educational resources and Clinical Practice, thereby connecting diverse disciplines of science.
His biological study spans a wide range of topics, including Phenotype, Hormone receptor, Hormone, Genotype and Estrogen receptor alpha. His Neoadjuvant therapy research incorporates themes from Randomized controlled trial, Proportional hazards model and Chemotherapy regimen, Chemotherapy. His Guideline study also includes
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
Cornelia Liedtke;Chafika Mazouni;Kenneth R. Hess;Fabrice André.
Journal of Clinical Oncology (2008)
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Roman Rouzier;Charles M. Perou;W. Fraser Symmans;Nuhad Ibrahim.
Clinical Cancer Research (2005)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado;C. Denkert;S. Demaria;N. Sirtaine.
Annals of Oncology (2015)
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
W. Fraser Symmans;Florentia Peintinger;Christos Hatzis;Radhika Rajan.
Journal of Clinical Oncology (2007)
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross;Elzbieta A. Slodkowska;W. Fraser Symmans;Lajos Pusztai.
Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial
Judy C. Boughey;Vera J. Suman;Elizabeth A. Mittendorf;Gretchen M. Ahrendt.
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
Katherine Stemke-Hale;Ana Maria Gonzalez-Angulo;Ana Lluch;Richard M. Neve.
Cancer Research (2008)
The Microarray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models
Leming Shi;Gregory Campbell;Wendell D. Jones;Fabien Campagne.
Nature Biotechnology (2010)
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Jeffrey S. Ross;Jeffrey S. Ross;Jonathan A. Fletcher;Gerald P. Linette;Gerald P. Linette;James Stec.
Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer
Kenneth R. Hess;Keith Anderson;W. Fraser Symmans;Vicente Valero.
Journal of Clinical Oncology (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: